Tempus AI Falls in After-Hours Despite Topping Q2 Estimates; Second-Half Outlook in Focus
NEW YORK, July 30, 2026, 18:00 EDT — Wall Street trading is closed for the day; after-market moves continue. Tempus ended the session up 6.6% at $44.29 before slipping 2.6% in after-hours trading. Revenue increased by 22% to $382.5 million, slightly surpassing analyst expectations. An initial assessment indicates a sharp increase in adjusted EBITDA for the second half.
How this was made
The 30-second read
Why it matters
The key trading question is whether Tempus can generate nearly $60M adjusted EBITDA in 2H to meet full-year guidance, given only $5.2M in 1H and unchanged management outlook.
Market read
Despite topping Q2 revenue expectations and raising full-year revenue guidance, Tempus shares sold off after-hours as traders scrutinize the adjusted EBITDA ramp required for the second half.
What to watch
The article notes GAAP net income was boosted by unrealized securities gains and that the Personalis financing structure could affect dilution/debt optics, both of which can distort the market’s interpretation of operating progress.
Background
Tempus posted Q2 results with a revenue beat and an updated 2026 revenue range, while investors focus on a steep adjusted EBITDA ramp needed in the second half.
Ticker impact
Tempus reported Q2 revenue of $382.5M (+22%) and raised full-year revenue guidance, but shares fell 2.6% after-hours on EBITDA-profitability scrutiny.
Near-term volatility likely persists as traders reprice the probability of reaching roughly $59.8M adjusted EBITDA in 2H versus the $5.2M achieved in 1H.
The article highlights a large second-half EBITDA step-up requirement (nearly $60M) versus first-half performance, while management keeps outlook unchanged; this creates a clear earnings-quality debate that can drive post-earnings trading.
Market effects
Diagnostic-testing and oncology testing peers moved similarly on the same day, suggesting broader risk-on sentiment in the group alongside company-specific profit-bridge concerns.
Primarily US small-to-mid cap growth sentiment, with after-hours repricing in the diagnostics/precision oncology space.
Limited direct global read-through; impact is mostly within US-listed precision oncology and diagnostics investors’ positioning.
Counterpoint
The revenue beat and raised 2026 revenue range may matter more than the near-term EBITDA bridge if margins improve as testing economics and AI/data licensing scale.
Key entities
- companyTempus AI
NASDAQ-listed precision oncology diagnostics and data/AI company reporting Q2 results and updated 2026 revenue guidance.
- companyPersonalis
MRD-focused company Tempus agreed to purchase in a deal valued around $1.5B, with financing that may increase debt and/or dilution.
- companyAstraZeneca
Partner referenced for supplying Tempus’s initial oncology foundation model, expected to provide upside later but not impacting current cash flow.
